Click Here if you would like a download of the latest brochure We are delighted to announce that Andrew Jack, Pharmaceutical Correspondent at The Financial Times will chair the FT Global Pharmaceutical & Biotechnology Conference

---

Transformation has become the by-word of an industry suffering the combined effects of patent expirations, declining R&D productivity, and increasing generic competition, but it has also become an imperative if the pharma companies are to survive and thrive in the current economic turmoil, and avoid the growing commoditisation of the industry. The recent wave of M&A is a sign of the accelerating trend, but how successful will the various transformation strategies being pursued and explored by the life science companies be in meeting the challenges the industry faces? What will the life sciences industry look like in a post-crisis world?

The FT Global Pharmaceutical and Biotechnology conference is Europe's pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives, 'feel the pulse' of the industry, and network with peers across the sector. This year's event is no exception and we have assembled a distinguished line-up of industry experts and commentators to share their views and perspective on the key trends that will reshape the life sciences industry for a post -crisis world.

Topics to be addressed at this year's conference include:

• Transforming the global life sciences industry-the pros and cons of alternative transformation strategies
• Are diversification strategies merely a side show to the main event-increasing productivity in the lab?
• Revisiting the pharma-bio innovation equation: the implications of the funding crisis for future innovation in the Industry-crisis or opportunity?
• Smart regulation-the key to radical transformation?
• Exploring new avenues for innovation, growth and profitability-the role of emerging markets
• US healthcare reform and the implications for the global life sciences industry